BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... The trials will assess the bispecific antibody in combination ...

No, Keytruda isn’t a chemotherapy drug. It’s an immunotherapy drug. Chemotherapy is a type of cancer treatment that kills cancer cells or stops them from multiplying (making more cells).

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...

Chemotherapy was associated with short-term cognitive dysfunction after treatment completion among patients with breast cancer. These findings were published in The Oncologist. Chemotherapy-induced ...

The clinical benefit rate observed and the median progression-free survival indicate a positive response to this novel chemotherapy-free approach ... events and the potential for Lymphir to enhance ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...